Literature DB >> 15094173

Basic treatment considerations using chemotherapy for patients with small cell lung cancer.

Bruce E Johnson1, Pasi A Jänne.   

Abstract

Entities:  

Mesh：

Year:  2004        PMID： 15094173     DOI： 10.1016/j.hoc.2003.12.008

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN： 0889-8588            Impact factor:   3.722


× No keyword cloud information.
  17 in total

1.  Association between serum tumor markers and metabolic tumor volume or total lesion glycolysis in patients with recurrent small cell lung cancer.

Authors:  Pengyue Shi; Xue Meng; Mengmeng Ni; Xindong Sun; Ligang Xing; Jinming Yu
Journal:  Oncol Lett       Date:  2015-09-03       Impact factor: 2.967

Review 2.  Small cell lung cancer: where do we go from here?

Authors:  Lauren Averett Byers; Charles M Rudin
Journal:  Cancer       Date:  2014-10-21       Impact factor: 6.860

3.  Irinotecan plus carboplatin in patients with extensive-disease small-cell lung cancer.

Authors:  Young Saing Kim; Se Hoon Park; Sun Young Kyung; Sun Jin Sym; Sang Pyo Lee; Jeong Woong Park; Sung Hwan Jung; Jinny Park; Eun Kyung Cho; Jae Hoon Lee; Dong Bok Shin
Journal:  Med Oncol       Date:  2010-03-03       Impact factor: 3.064

4.  Correlation between Semi-Quantitative (18)F-FDG PET/CT Parameters and Ki-67 Expression in Small Cell Lung Cancer.

Authors:  Soyeon Park; Eunsub Lee; Seunghong Rhee; Jaehyuk Cho; Sunju Choi; Sinae Lee; Jae Seon Eo; Kisoo Pahk; Jae Gol Choe; Sungeun Kim
Journal:  Nucl Med Mol Imaging       Date:  2016-01-05

5.  Small cell lung cancer.

Authors:  Gregory P Kalemkerian; Wallace Akerley; Paul Bogner; Hossein Borghaei; Laura Qm Chow; Robert J Downey; Leena Gandhi; Apar Kishor P Ganti; Ramaswamy Govindan; John C Grecula; James Hayman; Rebecca Suk Heist; Leora Horn; Thierry Jahan; Marianna Koczywas; Billy W Loo; Robert E Merritt; Cesar A Moran; Harvey B Niell; Janis O'Malley; Jyoti D Patel; Neal Ready; Charles M Rudin; Charles C Williams; Kristina Gregory; Miranda Hughes
Journal:  J Natl Compr Canc Netw       Date:  2013-01-01       Impact factor: 11.908

6.  Irinotecan-platinum combination therapy for previously untreated extensive-stage small cell lung cancer patients: a meta-analysis.

Authors:  Fei Xu; Xiaoli Ren; Yuan Chen; Qianxia Li; Ruichao Li; Yu Chen; Shu Xia
Journal:  BMC Cancer       Date:  2018-08-10       Impact factor: 4.430

7.  Increased Expression of Eps15 Homology Domain 1 is Associated with Poor Prognosis in Resected Small Cell Lung Cancer.

Authors:  Qingwei Meng; Weiling Sun; Man Li; Yanbin Zhao; Xuesong Chen; Lichun Sun; Li Cai
Journal:  J Cancer       Date:  2015-08-20       Impact factor: 4.207

8.  Survival analysis in second-line and third-line chemotherapy with irinotecan followed by topotecan or topotecan followed by irinotecan for extensive-stage small-cell lung cancer patients: a single-center retrospective study.

Authors:  Gokmen Aktas; Tulay Kus; Mehmet Emin Kalender; Alper Sevinc; Celaletdin Camci; Seval Kul
Journal:  Onco Targets Ther       Date:  2016-04-01       Impact factor: 4.147

9.  Clinical Significance of the Relationship between Progression-Free Survival or Postprogression Survival and Overall Survival in Patients with Extensive Disease-Small-Cell Lung Cancer Treated with Carboplatin plus Etoposide.

Authors:  Hisao Imai; Keita Mori; Nodoka Watase; Sakae Fujimoto; Kyoichi Kaira; Masanobu Yamada; Koichi Minato
Journal:  Can Respir J       Date:  2016-06-29       Impact factor: 2.409

10.  Clinical impact of post-progression survival on overall survival in elderly patients with extensive disease small-cell lung cancer.

Authors:  Hisao Imai; Keita Mori; Nodoka Watase; Toshifumi Kazama; Sakae Fujimoto; Kyoichi Kaira; Masanobu Yamada; Koichi Minato
Journal:  Thorac Cancer       Date:  2016-08-01       Impact factor: 3.500
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.